| Pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory melanoma (KEYNOTE-002): a randomised, controlled, phase 2 trial A Ribas, I Puzanov, R Dummer, D Schadendorf, O Hamid, C Robert, ... The lancet oncology 16 (8), 908-918, 2015 | 1762 | 2015 |
| Epidemiology of skin cancer J Reichrath, U Leiter, T Eigentler, C Garbe Sunlight, vitamin D and skin cancer, 120-140, 2014 | 810 | 2014 |
| Systematic review of medical treatment in melanoma: current status and future prospects C Garbe, TK Eigentler, U Keilholz, A Hauschild, JM Kirkwood The oncologist 16 (1), 5-24, 2011 | 740 | 2011 |
| Cutaneous, gastrointestinal, hepatic, endocrine, and renal side-effects of anti-PD-1 therapy L Hofmann, A Forschner, C Loquai, SM Goldinger, L Zimmer, S Ugurel, ... European journal of cancer 60, 190-209, 2016 | 682 | 2016 |
| Atezolizumab, vemurafenib, and cobimetinib as first-line treatment for unresectable advanced BRAFV600 mutation-positive melanoma (IMspire150): primary analysis of the … R Gutzmer, D Stroyakovskiy, H Gogas, C Robert, K Lewis, S Protsenko, ... The Lancet 395 (10240), 1835-1844, 2020 | 591 | 2020 |
| Neurological, respiratory, musculoskeletal, cardiac and ocular side-effects of anti-PD-1 therapy L Zimmer, SM Goldinger, L Hofmann, C Loquai, S Ugurel, I Thomas, ... European journal of cancer 60, 210-225, 2016 | 582 | 2016 |
| Baseline peripheral blood biomarkers associated with clinical outcome of advanced melanoma patients treated with ipilimumab A Martens, K Wistuba-Hamprecht, MG Foppen, J Yuan, MA Postow, ... Clinical Cancer Research 22 (12), 2908-2918, 2016 | 561 | 2016 |
| The price of tumor control: an analysis of rare side effects of anti-CTLA-4 therapy in metastatic melanoma from the ipilimumab network CJ Voskens, SM Goldinger, C Loquai, C Robert, KC Kaehler, C Berking, ... PloS one 8 (1), e53745, 2013 | 495 | 2013 |
| Direct injection of protamine-protected mRNA: results of a phase 1/2 vaccination trial in metastatic melanoma patients B Weide, S Pascolo, B Scheel, E Derhovanessian, A Pflugfelder, ... Journal of immunotherapy 32 (5), 498-507, 2009 | 467 | 2009 |
| Diagnosis, monitoring and management of immune-related adverse drug reactions of anti-PD-1 antibody therapy TK Eigentler, JC Hassel, C Berking, J Aberle, O Bachmann, V Grünwald, ... Cancer treatment reviews 45, 7-18, 2016 | 445 | 2016 |
| Palliative therapy of disseminated malignant melanoma: a systematic review of 41 randomised clinical trials TK Eigentler, UM Caroli, P Radny, C Garbe The lancet oncology 4 (12), 748-759, 2003 | 422 | 2003 |
| Results of the first phase I/II clinical vaccination trial with direct injection of mRNA B Weide, JP Carralot, A Reese, B Scheel, TK Eigentler, I Hoerr, ... Journal of immunotherapy 31 (2), 180-188, 2008 | 357 | 2008 |
| Evaluation of two dosing regimens for nivolumab in combination with ipilimumab in patients with advanced melanoma: results from the phase IIIb/IV CheckMate 511 trial C Lebbé, N Meyer, L Mortier, I Marquez-Rodas, C Robert, P Rutkowski, ... Journal of Clinical Oncology 37 (11), 867-875, 2019 | 326 | 2019 |
| Combined immune checkpoint blockade (anti-PD-1/anti-CTLA-4): evaluation and management of adverse drug reactions JC Hassel, L Heinzerling, J Aberle, O Bähr, TK Eigentler, MO Grimm, ... Cancer treatment reviews 57, 36-49, 2017 | 320 | 2017 |
| Malignant melanoma S3‐guideline “diagnosis, therapy and follow‐up of melanoma” A Pflugfelder, C Kochs, A Blum, M Capellaro, C Czeschik, T Dettenborn, ... JDDG: Journal der Deutschen Dermatologischen Gesellschaft 11 (s6), 1-116, 2013 | 309 | 2013 |
| Age and gender are significant independent predictors of survival in primary cutaneous melanoma K Lasithiotakis, U Leiter, F Meier, T Eigentler, G Metzler, M Moehrle, ... Cancer: Interdisciplinary International Journal of the American Cancer …, 2008 | 300 | 2008 |
| Diagnosis and treatment of cutaneous melanoma: state of the art 2006 C Garbe, TK Eigentler Melanoma research 17 (2), 117-127, 2007 | 286 | 2007 |
| Adjuvant nivolumab plus ipilimumab or nivolumab monotherapy versus placebo in patients with resected stage IV melanoma with no evidence of disease (IMMUNED): a randomised … L Zimmer, E Livingstone, JC Hassel, M Fluck, T Eigentler, C Loquai, ... The Lancet 395 (10236), 1558-1568, 2020 | 242 | 2020 |
| Prospective comparison of 18F-fluorodeoxyglucose positron emission tomography/computed tomography and whole-body magnetic resonance imaging in staging of advanced malignant … C Pfannenberg, P Aschoff, S Schanz, SM Eschmann, C Plathow, ... European Journal of Cancer 43 (3), 557-564, 2007 | 223 | 2007 |
| Incidence, mortality, and trends of nonmelanoma skin cancer in Germany U Leiter, U Keim, T Eigentler, A Katalinic, B Holleczek, P Martus, C Garbe Journal of Investigative Dermatology 137 (9), 1860-1867, 2017 | 220 | 2017 |
Dirk SchadendorfProfessor für Dermatologie, University Hospital Essen; University of Duisburg-Essen在 uk-essen.de 的电子邮件经过验证
